Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
Brian Bressler(University of British Columbia), Gerassimos J. Mantzaris(European CanCer Organisation), Andrés Yarur(Cedars-Sinai Medical Center), David T. Rubin(University of California System), Konstantinos Soufleris(Theageneio General Hospital), Udayakumar Navaneethan(AdventHealth Orlando), Emanuelle Bellaguarda(Northwestern University), Dirk Demuth(Takeda (Singapore)), Spyridon Michopoulos(Alexandra Hospital), Uri Kopylov(Sheba Medical Center), Pantelis Karatzas(Laiko General Hospital of Athens), Chris Fourment(Texas Digestive Disease Consultants), Andrew Singh(Research Canada), Dara Stein(EVRAZ (United Kingdom)), Anthie Gatopoulou(Democritus University of Thrace), Mark S. Silverberg(Sinai Health System), Marielle Bassel, Jesse Siffledeen(University of Alberta)
Cited by 148
Related Papers
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k